Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
91.56%
Net Margin
110.28%
Efficiency Metrics
Revenue per Expense Ratio
11.84
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
0.00%
EPS
1.7800000000
Balance Sheet Analysis
Current Ratio
0.07
Cash Ratio
0.00
Working Capital
$-144.89M
Debt to Equity
0.31
Debt to Assets
23.24%
Equity Ratio
75.01%
Cash Flow Analysis
Operating Cash Flow Ratio
70.60%
Free Cash Flow Ratio
70.60%
CapEx to Revenue
0.00%
Dividends Paid
$46.56M
Stock Buybacks
No buybacks
Total Shareholder Returns
$46.56M
Cash Position Change
-99.97%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 57.05%
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
732.95%
Net Income
561.80%
EPS
556.41%
Operating Income
14,422.87%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
1,481.02%
Operating Cash Flow
-62.54%
Free Cash Flow
-62.54%
Balance Sheet Health
Assets
3.41%
Debt
-1.52%
Book Value per Share
3.58%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
57.05%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
740.32%
5Y Revenue/Share
287.02%
3Y Dividend/Share
7.01%
5Y Dividend/Share
49.90%